ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myeloid Leukemia
Myelodysplastic Syndromes
Lymphoid Leukemia
Lymphoma

Leukemia trials near Pittsburgh, PA, USA:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib
Drug: Itraconazole

Phase 1, Phase 2

Kura Oncology

Pittsburgh, Pennsylvania, United States and 55 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Pittsburgh, Pennsylvania, United States and 43 other locations

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...

Enrolling
Chronic Myeloid Leukemia
Drug: KRT-232
Drug: Dasatinib

Phase 1, Phase 2

Kartos Therapeutics
Kartos Therapeutics

Pittsburgh, Pennsylvania, United States and 25 other locations

(CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, su...

Active, not recruiting
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Therapy-Related Acute Myeloid Leukemia
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

Phase 2

Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center

Pittsburgh, Pennsylvania, United States and 3 other locations

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Pittsburgh, Pennsylvania, United States and 171 other locations

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Pittsburgh, Pennsylvania, United States and 160 other locations

of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: Venetoclax

Phase 1

OncoVerity

Pittsburgh, Pennsylvania, United States and 22 other locations

safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...

Enrolling
LGLL - Large Granular Lymphocytic Leukemia
Aggressive NK Cell Leukemia
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Pittsburgh, Pennsylvania, United States and 36 other locations

plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed t...

Enrolling
Chronic Lymphocytic Leukemia
CLL
Drug: Bendamustine
Drug: Rituximab

Phase 3

BeOne Medicines

Pittsburgh, Pennsylvania, United States and 104 other locations

with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comor...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Decitabine and Cedazuridine (ASTX727)
Drug: Venetoclax

Phase 1, Phase 2

Taiho Pharma
Taiho Pharma

Pittsburgh, Pennsylvania, United States and 33 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems